Janux Therapeutics

We're gearing up to give our all for #cancer research. The Janux team has been hitting the pavement, the gym, and the trails again this year to prepare for this weekend's Curebound Cancer Challenge. Learn more: https://xmrrwallet.com/cmx.plnkd.in/gJDPMg2t #cureboundcancerchallenge #SanDiego 

Today at Janux’s virtual R&D Day, we showcased how we are using our TRACTr, TRACIr, and ARM platforms to create novel immunotherapeutics with the potential to address significant unmet needs in oncology and autoimmune diseases, including: 🔹 A PSMAxCD28-TRACIr program designed to be combined with JANX007, a potentially best-in-treatment asset, and provide CD28 co-stimulation to further differentiate depth and durability of patient responses. 🔹 A next-generation TROP2-TRACTr that adds a first-in-class opportunity targeting multiple solid tumors, with preclinical data supporting differentiated safety and efficacy potential. 🔹 A CD19-ARM program that demonstrated rapid, deep, and durable B-cell depletion in periphery and tissues with a prolonged memory B cell reset without CRS preclinically. Read the release for more and to access the webcast:  https://xmrrwallet.com/cmx.plnkd.in/gnrYxXiD #JANX #TCellEngagers #cancer #oncology #autoimmunedisease  #immunooncology  #immunotherapy #immunomodulator

We will be virtually hosting our first R&D Day on July 24, 2025. The event will include a presentation from management highlighting product candidates identified from its preclinical pipeline to move into clinical trials. These previously undisclosed preclinical programs utilize Janux’s expertise and platform technologies to potentially address significant unmet medical needs. For details on how to register for the event, see the press release: https://xmrrwallet.com/cmx.plnkd.in/gVJUNEta #JANX #TCellEngagers #immunotherapy #immunomodulator

We will be virtually hosting our first R&D Day on July 24, 2025. The event will include a presentation from management highlighting product candidates identified from its preclinical pipeline to move into clinical trials. These previously undisclosed preclinical programs utilize Janux’s expertise and platform technologies to potentially address significant unmet medical needs. For details on how to register for the event, see the press release: https://xmrrwallet.com/cmx.plnkd.in/gVJUNEta #JANX #TCellEngagers #immunotherapy #immunomodulator

Behind every scientific breakthrough and new therapeutic is a team of committed people making it all possible – in the lab, across the company, and everywhere in between. Meet Sandy Seril who plays a critical role in supporting our leadership and enabling our team to stay focused on our mission. For Sandy, commitment means giving her best every day, because she knows it helps Janux grow, thrive, and deliver on our mission to bring better treatment options to cancer patients. #Culture #CoreValues #LifeAtJanux #commitment #oncology #cancer

We’re pleased to welcome Janeen Doyle, as our new Chief Corporate and Business Development Officer. Janeen brings more than two decades of corporate strategy and business development experience across large pharma and biotech—most recently leading corporate partnerships and program development at Flagship Pioneering. Her deep expertise in building strategic partnerships and driving corporate growth will be instrumental as Janux advances its pipeline of TRACTr and TRACIr tumor-activated immunotherapies. Read more: https://xmrrwallet.com/cmx.plnkd.in/g-aqgtx7 #oncology #cancer #TRACTr #TRACIr #TCellEngagers #JANX

Today we reported our first quarter 2025 financial results and business highlights. We are pleased to have initiated expansion studies for JANX007 and continued enrolling patients in our Phase 1 trials for both JANX007 and JANX008, each designed to overcome the toxicity limitations of existing T cell engagers. We remain on track to share updated clinical data from these programs later this year and to host an R&D Day highlighting pipeline programs selected for clinical development. Read the press release for more: https://xmrrwallet.com/cmx.plnkd.in/gHhsZxpe    #Q1Earnings #ProstateCancer #cancer #TRACTr #TRACIr #TCellEngagers #JANX

We’re pleased to share that Janux has initiated Phase 1b expansion studies in our ongoing clinical trial evaluating JANX007, a PSMA-directed TRACTr therapeutic candidate, in patients with advanced metastatic castration-resistant prostate cancer (mCRPC). The initiation of the first expansion cohort is supported by updated data from the Phase 1a dose escalation portion of the trial. We look forward to sharing additional data from JANX007 and EGFR-TRACTr JANX008 at events in the second half of 2025. Separately, we will host an R&D Day in mid-2025 highlighting product candidates identified from our preclinical pipeline to move into clinical trials.   Read the press release for more: https://xmrrwallet.com/cmx.plnkd.in/ghvgPXcw   #ProstateCancer #cancer #TRACTr #TCellEngagers #JANX #mCRPC #Immunooncology

Behind every advance in cancer treatment is a discovery rooted in foundational science research. During National Cancer Research Month, we recognize the critical role of foundational research in shaping the future of cancer care. From understanding tumor biology to identifying new therapeutic targets, early-stage research fuels the innovation pipeline. Learn more from American Association for Cancer Research about the scientific community whose work lays the groundwork for tomorrow’s breakthroughs: https://xmrrwallet.com/cmx.plnkd.in/g6G4GgA #NCRM25 #CancerResearchSavesLives #UnitedByCancerResearch 

Spicing things up at Janux! 🌶️ Nothing brings a team together like a little friendly competition—and a lot of chili. We turned up the heat at our recent Janux Chili Cookoff, where team members served up their best recipes and even hotter banter. From mild and meaty to fiery and vegetarian, the flavor showdown was a delicious reminder of the creativity and camaraderie that make Janux such a special place to work. Big thanks to everyone who brought their A-game (and secret ingredients)! 👏 #TeamJanux